RIGL RIGEL PHARMACEUTICALS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1034842 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY2.2%
TTM net income YoY171.1%
TTM EPS YoY159.6%
Revenue 3-yr CAGR29.6%
Net income 3-yr CAGR—
Margins
Gross margin89.6%
Operating margin26.3%
Net margin106.6%
FCF margin—
EBITDA margin27.6%
Returns
ROE109.2%
ROA80.2%
ROIC (approx.)28.7%
Asset turnover0.75x
Leverage & solvency
Liabilities / assets15.0%
Debt / equity0.00x
Current ratio2.39x
Interest coverage18.17x
Cash quality & payout
Operating cash flow / net income0.29x
Accruals ratio56.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $294.28M | $179.28M | $116.88M | $120.24M | $149.24M |
| Cost of revenue | $19.62M | $18.65M | $7.11M | $1.75M | $1.08M |
| Gross profit | $274.66M | $160.63M | $109.77M | $118.49M | $148.15M |
| R&D expense | $33.30M | $23.38M | $24.52M | $60.27M | $65.24M |
| SG&A expense | $115.90M | $113.06M | $105.74M | $112.45M | $91.89M |
| Operating income | $125.47M | $24.19M | -$20.49M | -$55.55M | -$12.50M |
| Interest expense | $7.32M | $7.92M | $6.87M | $3.71M | $4.86M |
| Pretax income | $121.83M | $18.37M | -$25.09M | -$58.57M | -$17.31M |
| Income tax | -$245.20M | $881,000 | $0 | — | $605,000 |
| Net income | $367.02M | $17.48M | -$25.09M | -$58.57M | -$17.91M |
| EBITDA | $127.88M | $26.42M | -$19.25M | -$54.55M | -$11.33M |
| EPS (basic) | 20.40 | 0.99 | -1.44 | -3.44 | -0.11 |
| EPS (diluted) | 19.48 | 0.99 | -1.44 | -3.44 | -0.11 |
| Weighted avg. shares (diluted) | 18.84M | 17.69M | 17.40M | 17.05M | 170.49M |
| Balance sheet | |||||
| Cash & equivalents | $40.58M | $56.75M | $32.79M | $24.46M | $18.89M |
| Short-term investments | $114.38M | $20.57M | $24.15M | $33.75M | $106.08M |
| Receivables | $51.76M | $41.62M | $30.55M | $40.32M | $15.47M |
| Inventory | $11.51M | $6.00M | $5.52M | $9.12M | $6.62M |
| Current assets | $240.17M | $135.10M | $99.27M | $115.90M | $154.47M |
| PP&E, net | $30,000 | $92,000 | $165,000 | $857,000 | $2.18M |
| Intangibles | $24.75M | $27.10M | $13.88M | $14.95M | — |
| Total assets | $513.59M | $163.98M | $117.22M | $134.28M | $167.33M |
| Current liabilities | $99.24M | $63.30M | $53.27M | $65.21M | $63.55M |
| Long-term debt | $52.50M | $60.00M | $60.00M | $40.00M | $20.00M |
| Total debt | $52.50M | $60.00M | $60.00M | $40.00M | $20.00M |
| Total liabilities | $122.11M | $160.69M | $145.87M | $147.90M | $136.95M |
| Shareholders' equity | $391.48M | $3.29M | -$28.64M | -$13.62M | $30.37M |
| Net debt | $11.92M | $3.25M | $27.21M | $15.54M | $1.11M |
| Shares outstanding | 18.31M | 17.71M | 17.48M | 173.40M | 171.60M |
| Cash flow statement | |||||
| Operating cash flow | $75.66M | $31.47M | -$5.74M | -$73.76M | $5.88M |
| Capital expenditure | — | — | — | $450,000 | $627,000 |
| Free cash flow | — | — | — | -$74.21M | $5.25M |
| Investing cash flow | -$92.36M | $4.13M | -$4.30M | $72.78M | -$80.04M |
| Financing cash flow | $601,000 | -$11.64M | $18.37M | $6.55M | $62.67M |
| Depreciation & amortization | $2.42M | $2.23M | $1.24M | $998,000 | $1.16M |
| Stock-based compensation | $12.71M | $12.39M | $8.81M | $12.38M | $9.49M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.